Revici-E 250 Tablet
By Revici-E
Rx
10 Tablet in a Strip

Composition
Ethamsylate(250mg)

Manufacturer - Kee Pharma
Unit 531, 5th Floor, Paras Trade Centre, Gwal Pahari, Gurgaon - Faridabad Expressway, Gurgaon-122003

Expires on or after
October, 2025

liver
There is limited information available regarding the safety of using Revici-E 250 Tablet in individuals with liver disease. It is essential to seek guidance from your doctor before starting this medication if you have any liver concerns. Your healthcare provider can evaluate your specific situation and provide appropriate advice tailored to your health needs. Consulting with your doctor is crucial to ensure the safe and effective use of Revici-E 250 Tablet.

kidney
Limited information is available on using Revici-E 250 Tablet in kidney disease patients. It is advised to consult with your doctor.

alcohol
Consult your doctor when consuming alcohol with Revici-E 250 Tablet.

driving
Revici-E 250 Tablet does not typically impact driving ability.

pregnancy
Revici-E 250 Tablet may not be safe during pregnancy. Limited human studies suggest potential harm to the baby. Animal studies show harmful effects on fetal development. Your doctor will assess risks versus benefits before prescribing. Please consult your doctor before using it.

breastfeeding
It is better to consult your doctor before using Revici-E 250 Tablet during breastfeeding.
Habit Forming | No |
Chemical Class | Benzenesulfonate Derivative |
Therapeutic Class | BLOOD RELATED |
Action Class | Haemostatic agent |
₹129.15
Inclusive of all taxes
Content verified by

Dr. Gowri Kulkarni
MBBS - General Medicine, DNB - Psychiatry, MRCGP [INT] Family Medicine, BSIC (BACP)
Last update on 11-Feb-2025